CJC-1295 & Ipamorelin: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. This blend combines two research compounds — CJC-1295 and Ipamorelin — neither of which is approved by Health Canada or the FDA for the research applications described in this guide.

Last updated: July 2026

---

This is the most widely used combination in the entire growth hormone axis category, and for good reason — it’s the pairing the individual mechanisms actually point toward. CJC-1295 and Ipamorelin activate two completely separate receptor pathways that converge on the same pituitary cells, and using them together is less a matter of preference than of following where the pharmacology leads. This guide covers what’s specific to using them pre-blended.

Quick Facts

Contains	CJC-1295 (no DAC) and Ipamorelin
Standard ratio	1:1 — typically 5mg/5mg (10mg total)
Primary research use	Amplified growth hormone pulse — body composition, recovery, sleep quality
Administration	Subcutaneous, bedtime, fasted
Typical effective range (community-reported)	250mcg of each compound, once daily
Evidence tier	Same as the individual compounds — no blend-specific human trials exist
Regulatory status	Both components discussed in this guide series’ individual guides; both currently sit in the same FDA compounding-classification gap; both named in Health Canada’s April 2026 advisory

Why These Two, Together

CJC-1295 activates the GHRH receptor. Ipamorelin activates a completely separate receptor — GHSR, the ghrelin receptor. Both receptors sit on the same pituitary somatotroph cells, and activating both at once produces a growth hormone pulse substantially larger than either compound produces alone — not because they’re each individually more potent in combination, but because two independent signals converging on the same cells amplify each other in a way neither can replicate alone.

This is a genuinely different rationale than the regenerative blends covered elsewhere in this guide series, where the components address different parts of a process (repair activation, mobilization, structural support). Here, both compounds are aiming at the exact same outcome — a larger GH pulse — through two different doors. For the complete individual profiles, including the specific evidence and mechanism detail behind each compound, see our dedicated CJC-1295 and Ipamorelin guides, and our Growth Hormone Axis Group comparison for how this pairing stacks up against Tesamorelin-based alternatives.

The Version That Matters

Confirming which version of CJC-1295 is in this blend matters as much here as it does when buying CJC-1295 on its own. This blend uses CJC-1295 without DAC — the short-acting version that produces a clean, natural pulse, matched to Ipamorelin’s own short half-life and once-daily administration pattern. CJC-1295 with DAC, the long-acting, once-weekly version, is a fundamentally different pharmacokinetic tool and isn’t what’s typically blended with Ipamorelin for daily use — the two dosing schedules (once daily versus once weekly) don’t fit together the way the no-DAC version does. If a vendor’s blend doesn’t specify which version is included, that’s worth clarifying directly before ordering.

The Evidence, As a Combination

As with every blend in this guide series, there is no human trial evidence for this specific combination as a product — no completed study has evaluated CJC-1295 and Ipamorelin administered together in humans for the outcomes researchers actually pursue with it.

What exists is the individual evidence base for each compound, and it’s worth carrying forward a key point from both individual guides directly: CJC-1295’s human data (a 2006 Phase 1 study) studied the DAC formulation, not the no-DAC version actually used in this blend, and Ipamorelin’s only completed human trial tested an unrelated indication (postoperative gut motility) and failed its primary endpoint. Neither compound has direct human efficacy data for the outcomes this blend is researched for, let alone the combination itself. The synergistic-pulse mechanism is well-supported preclinical pharmacology — real, published animal and cell-model research confirming both receptors converge on GH release — but that’s a different claim than a human trial demonstrating the combination improves body composition, sleep, or recovery.

Who Shouldn’t Use This

This blend combines the individual cautions of both components.

• Personal or family history of cancer or active malignancy. Both compounds carry the same theoretical IGF-1-related concern individually, and CJC-1295 specifically carries a more concrete, named safety signal — FDA documentation from its 2023 compounding classification cited cardiac adverse events and preclinical pituitary-cell DNA damage findings.
• Known cardiac conditions. This is specific to the CJC-1295 component and worth taking seriously given the named signal above.
• Pregnancy or breastfeeding. No human safety data exists for either component in this context.

See our individual CJC-1295 and Ipamorelin guides for the complete picture on each compound’s specific safety considerations.

Common Myths, Addressed

“This combination has been clinically proven to work together.” Not accurately — no human trial has tested CJC-1295 and Ipamorelin together for any outcome. The synergistic mechanism is well-supported preclinical pharmacology, not a demonstrated clinical result.

“Since both compounds individually lack strong human efficacy data, the combination is unlikely to do anything.” This doesn’t follow either — a lack of direct trial evidence for either compound’s current use case doesn’t mean the underlying receptor pharmacology (which is genuinely well-established) fails to produce the proposed physiological effect. It means the leap from “the mechanism is real” to “the outcomes people want are demonstrated in a trial” hasn’t been completed for either compound, individually or combined.

“More of both compounds means proportionally more effect.” As covered in the individual CJC-1295 guide, the pituitary’s GHRH receptors have a saturation point — beyond a certain threshold, more compound doesn’t produce a proportionally larger pulse. This applies within the blend just as it does to CJC-1295 alone.

What Researchers Are Actually Experiencing

Community-reported experience for this blend closely mirrors what’s described in each individual guide, since the two compounds are typically administered together in the same injection anyway. Vivid dreams, water retention, and mild joint discomfort are the most frequently mentioned effects, particularly in the first few weeks. A full-body warmth or flush following administration is also commonly reported.

Timing and fasting come up as consistently for the blend as for either compound alone — insulin suppresses the GH axis, so a 2–3 hour fast before bedtime administration is standard community practice for both components simultaneously.

This section reflects patterns commonly discussed across community research spaces. It’s observational rather than clinical trial data, and individual experience varies.

The Practical Basics

Research Ranges

Protocol	Dose (each compound)	Timing
Conservative	100mcg	Bedtime, fasted 2–3 hours
Standard	250mcg	Bedtime, fasted 2–3 hours
Active	300mcg	Bedtime, fasted 2–3 hours

Both compounds are dosed at the same amount as each other in this blend, consistent with its 1:1 ratio — 250mcg of CJC-1295 alongside 250mcg of Ipamorelin is the community standard.

Worked Dose Math

At a 10mg total blend (5mg CJC-1295 + 5mg Ipamorelin) reconstituted with 2mL BAC water — a standard 3mL vial capacity — the combined concentration is 5mg/mL, or 2.5mg/mL of each individual compound:

• 100mcg of each compound → 0.04mL → 4 units (delivers 100mcg CJC-1295 + 100mcg Ipamorelin together)
• 250mcg of each compound → 0.1mL → 10 units (delivers 250mcg CJC-1295 + 250mcg Ipamorelin together)
• 300mcg of each compound → 0.12mL → 12 units (delivers 300mcg CJC-1295 + 300mcg Ipamorelin together)

The underlying rule is the same as any single-compound calculation: volume (mL) = dose (mg) ÷ concentration (mg/mL), then ×100 for units on a U-100 syringe — each unit drawn delivers both compounds simultaneously at the blend’s 1:1 ratio.

Vial Planning

A 10mg vial (5mg/5mg) at 2.5mg/mL of each compound gives you 5mg of each total. At a steady 250mcg of each per day, that’s 20 days per vial.

Reconstitution and Storage — The Short Version

This blend reconstitutes with standard BAC water, refrigerates at 2–8°C, and should be used within 28 days — the same standard approach used across nearly every compound in this series. For the complete process, see our dedicated reconstitution guide and storage guide.

Sourcing

Confirming the CJC-1295 component is the no-DAC version is the single most important sourcing check specific to this blend. Beyond that, a complete Certificate of Analysis should confirm the identity and purity of both components independently. See our full guide on reading a Certificate of Analysis and vetting a vendor for the general framework this builds on.

Administration

Subcutaneous injection, once daily, bedtime, fasted 2–3 hours. Some researchers use a five-days-on, two-days-off weekly schedule rather than daily administration.

Best Practices

• Confirm the no-DAC version before ordering — this is the single highest-leverage sourcing check for this specific blend.
• Protect your fasting window — this matters as much for the blend as for either compound individually.
• Build a cycling schedule into your protocol — 8 weeks on followed by 8 weeks off is a commonly discussed community pattern, alongside 5-days-on/2-days-off within active periods.
• Track your protocol from day one — dose, timing, fasting duration, and observed effects, at minimum.

Blend vs. Buying Separately

The tradeoff here is similar to the regenerative blends covered elsewhere in this guide series: a fixed 1:1 ratio you can’t independently adjust, versus separate vials that let you run different relative doses of each compound if your research plans call for it. Because both compounds are typically administered in the same injection regardless of whether they’re pre-blended or drawn from separate vials, the practical convenience gap between the two approaches is fairly modest — the real decision point is ratio flexibility, not administration convenience.

Common Mistakes to Avoid

• Not confirming which CJC-1295 version is in the blend — the with-DAC and no-DAC versions aren’t interchangeable, and this blend is built around the no-DAC pharmacokinetic profile specifically.
• Skipping the fasting window, which directly undermines the mechanism both compounds depend on.
• Assuming higher combined doses produce proportionally larger effects beyond the pituitary’s saturation point.
• Not recording the reconstitution volume, turning every dose calculation into a guess.

What Happens If You Stop

As with each individual component, there’s no dedicated discontinuation research for this blend. Because both compounds work by amplifying the body’s own pulsatile GH release rather than replacing it directly, there’s no clear mechanistic reason to expect a withdrawal-style rebound — any downstream effects on body composition, sleep, or recovery would reasonably be expected to fade as GH and IGF-1 levels return toward baseline after stopping. This is a reasonable inference from the mechanism, not a documented finding.

What to Expect, Week by Week

This follows the same general pattern described in the individual CJC-1295 and Ipamorelin guides — some researchers report the flush and improved sleep within the first several administrations, with recovery and sleep-quality reports tending to consolidate over the first two to four weeks, and any body composition changes generally described as gradual rather than early and dramatic.

Common Questions

Is this blend more effective than using CJC-1295 or Ipamorelin alone? The proposed mechanism (two independent receptor pathways converging on the same cells) supports a larger combined GH pulse than either compound alone, and this is well-established preclinical pharmacology. No human trial has directly tested the combination against either compound individually to confirm the magnitude of that difference in the outcomes researchers care about.

Why does the blend specifically use no-DAC CJC-1295? Because its once-daily, short-acting pulse pattern matches Ipamorelin’s own dosing schedule. The once-weekly, long-acting DAC version doesn’t fit the same daily administration pattern.

Can I adjust the ratio if I want more of one compound than the other? Not within a fixed pre-blended vial — that requires separate vials, dosed independently.

Is this blend legal to source in Canada? Each component is subject to the considerations described in our Canadian regulatory guide, and both were named in Health Canada’s April 2026 advisory individually. Combining them into one product doesn’t change that underlying status.

Before You Start

A quick checklist to run through before your first dose:

• [ ] Confirmed the CJC-1295 component is the no-DAC version
• [ ] Considered whether you have a personal history of cancer or a cardiac condition, and sought medical guidance if so
• [ ] Planned your fasting window around your injection timing
• [ ] Have a tracking method ready for dose, timing, and observed effects
• [ ] Planned a cycling schedule rather than indefinite continuous use

Want this as a printable checklist alongside our compound reference plate? Download both from the resources section.

Common Protocol at a Glance

Protocol	Dose (each compound)	Timing
Conservative	100mcg	Bedtime, fasted
Standard	250mcg	Bedtime, fasted
Active	300mcg	Bedtime, fasted

Where to Go From Here

• CJC-1295: The Complete Guide
• Ipamorelin: The Complete Guide
• Tesamorelin: The Complete Guide
• The Growth Hormone Axis Group — all three compared in full
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.